Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

(Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will leverage Graph's lab-in-the-loop platform ...

Parse Biosciences & Graph Therapeutics partner to build large functional immune perturbation atlas: Seattle Thursday, January 22, 2026, 11:00 Hrs [IST] Parse Biosciences, a global ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

Both events were tragic, but they didn’t ­involve people I was directly connected to. When I was young, my friends and ...

Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment and participant ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

Mental health conditions such as alcohol use disorder and PTSD could significantly increase risk for liver cancer among ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

Individuals with incidentally detected splenomegaly may be at increased risk for blood and liver cancers, as well as cirrhosis.An evaluation of more than 47,000 individuals who had a CT or MRI found ...

Large language models (LLM) can generate treatment recommendations for straightforward cases of hepatocellular carcinoma (HCC ...

Immunotherapy-based combinations have rapidly replaced tyrosine kinase inhibitors as first-line treatment for advanced hepatocellular carcinoma, reshaping real-world practice over the past decade. In ...